|
Name |
Ethanone, 2-(5-methoxy-1-methyl-2-benzimidazolyl)thio-1-phenyl-
|
Molecular Formula | C17H16N2O2S | |
IUPAC Name* |
2-(5-methoxy-1-methylbenzimidazol-2-yl)sulfanyl-1-phenylethanone
|
|
SMILES |
CN1C2=C(C=C(C=C2)OC)N=C1SCC(=O)C3=CC=CC=C3
|
|
InChI |
InChI=1S/C17H16N2O2S/c1-19-15-9-8-13(21-2)10-14(15)18-17(19)22-11-16(20)12-6-4-3-5-7-12/h3-10H,11H2,1-2H3
|
|
InChIKey |
GBLIMXOJGGWMEW-UHFFFAOYSA-N
|
|
Synonyms |
CBMicro_027077; Oprea1_046946; DTXSID101166315; Ethanone, 2-(5-methoxy-1-methyl-2-benzimidazolyl)thio-1-phenyl-; 2-[(5-Methoxy-1-methyl-1H-benzimidazol-2-yl)sulfanyl]-1-phenylethanone #; 2-[(5-Methoxy-1-methyl-1H-benzimidazol-2-yl)thio]-1-phenylethanone; 302929-97-1
|
|
CAS | 302929-97-1 | |
PubChem CID | 570087 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 312.4 | ALogp: | 3.5 |
HBD: | 0 | HBA: | 4 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 69.4 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.521 |
Caco-2 Permeability: | -4.69 | MDCK Permeability: | 0.00002340 |
Pgp-inhibitor: | 0.142 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.916 | Plasma Protein Binding (PPB): | 98.72% |
Volume Distribution (VD): | 0.409 | Fu: | 0.90% |
CYP1A2-inhibitor: | 0.989 | CYP1A2-substrate: | 0.896 |
CYP2C19-inhibitor: | 0.963 | CYP2C19-substrate: | 0.11 |
CYP2C9-inhibitor: | 0.923 | CYP2C9-substrate: | 0.861 |
CYP2D6-inhibitor: | 0.827 | CYP2D6-substrate: | 0.641 |
CYP3A4-inhibitor: | 0.911 | CYP3A4-substrate: | 0.32 |
Clearance (CL): | 8.098 | Half-life (T1/2): | 0.337 |
hERG Blockers: | 0.646 | Human Hepatotoxicity (H-HT): | 0.12 |
Drug-inuced Liver Injury (DILI): | 0.873 | AMES Toxicity: | 0.903 |
Rat Oral Acute Toxicity: | 0.032 | Maximum Recommended Daily Dose: | 0.663 |
Skin Sensitization: | 0.878 | Carcinogencity: | 0.832 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.956 |
Respiratory Toxicity: | 0.906 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002396 | 0.352 | D0J1MI | 0.400 | ||||
ENC004474 | 0.347 | D0R1RS | 0.347 | ||||
ENC001456 | 0.341 | D0G1VX | 0.341 | ||||
ENC000077 | 0.341 | D0J6WW | 0.341 | ||||
ENC000732 | 0.341 | D09VXM | 0.340 | ||||
ENC005605 | 0.341 | D05CKR | 0.337 | ||||
ENC000174 | 0.338 | D0L5PO | 0.337 | ||||
ENC000209 | 0.333 | D09LZT | 0.333 | ||||
ENC000093 | 0.333 | D02IHW | 0.333 | ||||
ENC001354 | 0.333 | D0W9WF | 0.333 |